Barry R Keith

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

M. Berger, M. Untch, R. Finn, 2006, Cancer research.

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Hong Ma, Krystal J Alligood, G. Owens, 2002, Oncogene.